Ramelius Resources bids to buy Tampia Hill’s gold miner Explaurum Limited

Ramelius Resources Limited

Ramelius Resources Limited (ASX:RMS) has announced an off-market takeover bid offer to buy Brisbane-based gold exploration and development company, Explaurum Limited for $59 million. The acquisition offer comes after the strategic attempt to gain control over Explaurum’s Tampia Hill Project, located in the wheat belt of Western Australia, approximately 240km east of Perth.

The acquisitive gold miner Ramelius Resources has offered one Ramelius share for every four Explaurum shares held at an offer price of $0.123, reflecting 66.2% premium to the last closing price of Explaurum shares. However, the company has provided that the offer is not subject to any minimum acceptance threshold. 

As per the company’s information, the acquisition seems to bring operational and capital cost synergies between Explaurum’s Tampia Hill Project and Ramelius’ 100% owned Edna May mine, while keeping the pace with ongoing exploration potential.

Although the offer claims to reduce Explaurum Shareholder risks associated with high debt levels, uncertainty over access to funding and dilutive capital raisings, Explaurum released a statement on the same day suggesting its shareholders to take no action in response to the offer. The Board of Explaurum Limited believes that this takeover bid has undervalued Explaurum’s assets.

For FY18 Ramelius reported net profit after tax of $30.8 million, an increase of 74% on FY17 NPAT. In the same year company has achieved record production of 208,118 ounces of gold, up 66% on FY17, for the full year ended 30 June 2018.

After falling 4.255% on the day of takeover bid announcement, i.e. 10 September 2018, RMS dropped by 1.111% to $0.445 on 11 September 2018.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report